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 Abstract 
Reliable estimation methods for non-linear mixed-effects models are now available and, 
although these models are increasingly used, only a limited number of statistical 
developments for their evaluation have been reported. We develop a criterion and a test to 
evaluate nonlinear mixed-effects models based on the whole predictive distribution. For 
each observation we define the prediction discrepancy (pd) as the percentile of the 
observation in the whole marginal predictive distribution under H0. We propose to 
compute prediction discrepancies using Monte Carlo integration which does not require 
model approximation. If the model is valid, these pd should be uniformly distributed over 
[0, 1] which can be tested by a Kolmogorov-Smirnov test. In a simulation study based on 
a standard population pharmacokinetic model, we compare and show the interest of this 
criterion with respect to the one most frequently used to evaluate nonlinear mixed-effects 
models: standardized prediction errors (spe) which are evaluated using a first order 
approximation of the model. Trends in pd can also be evaluated via several plots to check 
for specific departures from the model. 
 
 
KEY WORDS: model evaluation; population pharmacokinetics; predictive 
distribution; prediction errors. 
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 INTRODUCTION 
Nonlinear mixed-effects models in drug development 
 Nonlinear mixed-effects models are increasingly used for population analysis of 
pharmacokinetic or pharmacodynamic longitudinal data, especially during drug 
development (1,2). Several assumptions are needed to build these models: (i) for the 
structural model of the process under study, in most cases nonlinear with respect to the 
parameters, (ii) for the model of the inter-individual variability of the parameters, i.e. 
assumptions regarding the model and distribution of the random effects, (iii) for the 
error model.  The model and estimated population parameters obtained from such 
analyses are now often used for simulation of clinical trials, an area which is also of 
growing importance in drug development (3–5). Providing evidence for the quality of 
the results is important for their use both in the different phases of drug development 
before registration and for dose recommendation for patients in routine clinical 
practice. We therefore fully agree with Yano, Beal and Sheiner who wrote (6): “As 
complex models depend on many assumptions, and their sensitivity to these is not 
immediately apparent, evaluation of such models is attaining new importance”. 
 In this paper, we restrict ourselves to the most popular statistical approach in this 
field: maximum likelihood estimation (MLE) with normality assumption for the 
distribution of the random-effects. Because the model is nonlinear, there is no closed 
form for the likelihood. The first estimation method proposed in the context of 
nonlinear mixed-effects models was the First-Order (FO) method, based on a 
linearisation of the model. There are now several estimation algorithms available (7–
9), implemented in different software (10). Dedicated software, such as NONMEM 
(11), P-Pharm (12) or WinNonMix (Pharsight Corporation, Mountain View, CA), 
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 have been developed and more standard statistical packages also provide estimation 
tools, such as the nlme function (9) in Splus  or  the NLMIXED procedure (13) in 
SAS.   
 
Model evaluation, validation, adequacy, assessment, checking, appropriateness, 
performance … 
 There is large statistical literature on model evaluation, especially from Bayesian 
statisticians. It is a complex issue in statistical modelling and it has several 
terminologies. Gelfand (14) started the chapter on model determination in a book on 
Monte Carlo Markov Chains applications by: “Responsible data analysis must address 
the issue of model determination, which consists in two components: model 
assessment or checking and model choice or selection. Since, in practice, apart from 
rare situations, a model specification is never ‘correct’ we must ask (i) is a given 
model adequate? and (ii) within a collection of models under consideration, which is 
the best?” . We focus here on question (i), model adequacy.  
 In 1997, Mentré and Ebelin (15) defined in population pharmacokinetics model 
validation as the assessment of the predictability of the model and estimates for further 
inferences. The same definition is used in the guidance on Population 
Pharmacokinetics of the Food and Drug Administration published in 1999 (16), in 
which there is a section devoted to model validation. Mentré and Ebelin (15) also 
noted that in chapter 6 about model checking in their book published in 1995, Gelman, 
Carlin, Stern and Rubin (17) wrote: “We do not like to ask, ‘Is our model true or false 
’, since probability models in most data analyses will not be perfectly true. The more 
relevant question is, ‘Do the model’s deficiencies have a noticeable effect on the 
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 substantive inferences?’”.  
 Yano, Beal and Sheiner proposed to use the term model evaluation as they 
explained in a note in their paper published in 2001 (6): “We use the weaker term 
‘evaluation’ rather than the stronger one ‘validation’, as we believe one cannot truly 
validate a model, except perhaps in the very special case that one can both specify the 
complete set of alternative models that must be excluded and one has sufficient data to 
attain a preset degree of certainty with which these alternatives would be excluded. 
We believe that such cases are rare at best”.  
 Williams and Ette, in 2003, used the term model appropriateness in the title of their 
chapter in the book on Simulation for Designing  Clinical trials (18), of which they 
then defined two different aspects: model evaluation and model validation. In the 
present paper, we rather follow the terminology of Yano, Beal and Sheiner (6), i.e. 
model evaluation, with the definition they gave: “The goal of model evaluation is 
objective assessment of the predictive ability of a model for domain-specific quantities 
of interest, or to determine whether the model deficiencies (the final model is never 
the ‘true model’) have a noticeable effect in substantive inferences.”   
 
Methods of evaluation of nonlinear mixed-effects models 
 Although reliable estimation methods for non-linear mixed-effects models are now 
available, only a limited number of statistical developments for evaluation of the 
results or model checking have been reported in this area (15,6,18). 
 Model evaluation can be done either on the original data set used for estimation 
(usually called internal validation), or, preferably, on a separate data set (usually 
called external validation). For “internal validation” several methods have been 
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 proposed: one approach is to randomly split the initial data set, others are to use cross-
validation approaches or bootstrap methods (15,6,18). It is not our purpose here to 
discuss whether random splitting, as proposed by the Food and Drug Administration 
(16), is the most appropriate approach for “internal validation”. This debate is beyond 
the scope of this paper, and has been the subject of more general discussion in the 
statistical literature on model checking, as for instance by Evans (19).  
 Here, we are interested in a criterion to evaluate the “distance” between the 
observed values and the model predictions in order to derive a statistical test of model 
adequacy. Most estimation software in nonlinear mixed-effects models evaluate the 
standardized prediction errors (spe). This criterion is currently the most frequently 
used for model evaluation in this area (18). The standardized predictions errors are 
derived, for each observation, from the mean predicted value and its variance, 
computed using a first-order approximation of the model like in the FO approach. A 
test is then often performed to see whether they follow a normal distribution, an 
assumption also based on the FO linearisation.  
 There have been several papers on the problem of investigating whether a given 
null model H0 is compatible with data, in the situation where the assumed model has 
unknown parameters (20,21). These authors proposed and discussed several p-values 
for what they called composite null models in the frequentist or the Bayesian view. To 
our knowledge they did not address the issue of mixed-effects models. Lange & Ryan 
(22) developed a method to assess normality of random effects in linear mixed effects 
models using empirical cumulative distribution of the empirical Bayes estimates of the 
random effects.  
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Predictive distribution 
 The idea of using the whole predictive distribution for model evaluation has been 
proposed by Gelfand, Det and Chang (23) in a Bayesian framework and is also 
discussed by Gelman, Carlin, Stern and Rubin (17). It has been used for example by 
Best, Tan, Gilks and Spiegelhalter (24) to evaluate the model obtained in a population 
pharmacokinetic analysis in children on two separate data sets. Yano, Beal and 
Sheiner extended the idea to the non-Bayesian setting and defined posterior predictive 
check (PPC) which they applied and evaluated in individual nonlinear regression. 
They proposed three approaches to compute the posterior distribution of the 
parameters estimated through MLE. The simplest approach, which we use also here, is 
to use what they called a “degenerate” distribution: the posterior distribution is 
approximated by a discrete distribution with one location at the maximum likelihood 
estimate. That is to say, the estimation error is not taken into account, which can be 
reasonable in large enough data sets. This approach, based only on the maximum 
likelihood estimates, is called the “plug-in” approach in the papers by Bayarri and 
Berger (20) and Robins, van der Vaart and Ventura (21). 
 In the present paper, we propose a criterion to evaluate the predictability of an 
observation by a model without approximation. This criterion can be viewed as a 
“distance” between an observation and its prediction. It is an extension of the notion 
of residuals or of prediction errors which are the differences between observations and 
fitted or predicted values. We evaluate what we call the “prediction discrepancy” (pd) 
which is defined as the percentile of an observation in the whole marginal predictive 
distribution under H0. This approach has already been applied for the evaluation of the 
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 population pharmacokinetic analysis of an anti-histaminic drug during its development 
after random splitting of the original data set with 2/3 of the patients for model 
building and 1/3 for model evaluation (25). In that study, a nonparametric estimation 
method was used (26) and the estimated distribution was discrete; there was therefore 
a closed form for the evaluation of the prediction discrepancies. In the more usual case 
of parametric MLE methods which we consider here, we propose to calculate the 
prediction discrepancies by Monte-Carlo integration.This approach has been 
successfully applied to detect the differences of the pharmacokinetics of S1, an oral 
anticancer agent, in Western and Japanese patients using NONMEM (27).  
 The method is described in details in the next section. Because the distribution of 
pd is uniform U[0,1] under H0, a Kolmogorov-Smirnov (KS) test can be used to test 
model adequacy. In the following section, we illustrate the use of pd in the context of 
a basic population pharmacokinetic model and we evaluate by simulation the type I 
error and the power of the proposed test for a number of alternative hypotheses. We 
also compare the performances of the tests based on pd to those based on spe.  
 
METHODS 
Model 
 Let yi be the ni-vector of observations observed in individual i (i=1,…, N). We 
assume that there is a known function f describing the non-linear structural model and 
that the error model is additive. The individual regression model is then given by yi = 
f(θi, ξi) + εi, where  is the nTini1 )t,...,(t i=iξ i-vector of sampling times for individual i, 
θi is the p-vector of individual parameters and εi is the ni -vector of random errors with 
εi ~ N(0, Σi(θi)). Σi(θi) are assumed to be ni × ni -diagonal matrices.  
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  The model for the variance of the residual error of the jth observation of individual i 
is  assumed to be given by a known function h which may depend on θi but also on 
additional variance parameters σ  and β: var(εij) = σ2 h(tij, θi, β). If a constant error 
model is assumed, the function h is equal to one and σ2 is the variance of the residual 
error. If a constant coefficient of variation error model is assumed, h is equal to f2 and 
σ is the coefficient of variation. In these two cases there is no additional variance 
parameter β, but more complex error models can be used.   
 As usual, εi | θi, i=1,…, N, are assumed to be independent from one individual to the 
other, and for each individual, εi  and θi  are also independent. The model for inter-
individual variability of the parameters involves individual vectors of random effects, 
bi, and a vector μ of fixed effects. The individual parameters are modelled either by 
θi = μ + bi , for an additive random-effects model, or by θi  = μ exp( bi), for an 
exponential random-effects model. It is assumed that bi ~ N( 0, Ω), with Ω  defined as 
a p×p- matrix, where each diagonal element ωkk represents the variance of the kth 
component of the random effects vector.  
 
Predictive Distribution 
 We assume that the population model and the population parameters, 
μ, diag(Ω), σ, β, are given and that they define the null model H0. We want to evaluate 
the predictive distribution of the observations in an individual i. Assuming that the 
population parameters were obtained by maximum likelihood, we consider here only 
the point estimates and discard the estimation error as in the plug-in approach defined 
by Bayarri and Berger (20) and Robbins, van der Vaart and Ventura (21). For each 
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 vector of observation yi, given the associated experimental design ξi, the model and 
the population parameters, we can compute the associated predictive distribution pi(y), 
defined as: 
∫i (y)p iii )dθp(θ)θp(y= .                                                       (1) 
Because of the assumptions on the error model, p(y | θi) is normal with mean f(θi , ξi) 
and variance Σi(θi) = diag(σ2 h(tij, θi, β)). When the structural model is nonlinear, there 
is no analytical expression for the integral in pi(y). This is a well known fact which has 
prompted the first-order approximations proposed for maximum likelihood estimation 
in that case.  
 We propose to approximate the distribution pi(y) by a discrete distribution, by 
stochastic simulation of K values of bk in N(0, Ω) and to evaluate θk with the 
appropriate model. The predictive distribution can then be estimated by Monte Carlo 
integration, and approximated  by a mixture of K normal distributions with weights 
1/K, means f(θk, ξi) and variances Σi(θk):  
( )kiik ,)θ(Σ),ξ,θf(;∑∑
==
==
K
1k
K
1k
ki yK
1)θyp(
K
1)y(p φ                           (2) 
where φ(x; μ, Ω) is the multivariate normal density function with mean μ and variance 
Ω evaluated at x. This expression does not use a linearisation of the structural model 
but uses instead stochastic integration using random samples from the normal 
distribution, and K can be chosen large enough to provide a good approximation. 
 
Prediction Discrepancy 
 We use the full predictive distribution to define the prediction discrepancy for the 
jth observation of individual I, pdij. Let Fij be the cumulative distribution function of 
the predictive distribution pi(yij) given in Eq. (1). The prediction discrepancy is 
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 defined by the evaluation of Fij at yij, and is given by:  
.dy)dθp(θ)θp(y iii)(yFpd
ijy
ijijij ∫ ∫==     (3) 
pdij is the percentile of the observation yij in the marginal distribution of the 
observations under H0.  If the model and population parameters are correct, these 
prediction discrepancies should follow a uniform distribution over [0, 1]. This well 
known result on the cumulative distribution function is always true under H0 and does 
not require any approximation.  
 The prediction discrepancies can be evaluated by stochastic integration using a 
random sample of values θk as in Eq. (2). Then Fij (yij) is evaluated by: 
∑∫
=
K
1k
k
y
)dy.θyp(
K
1 ij∫ ∑
=
== y
K
1k
kijij )dyθp(yK
1)(yF ij          (4) 
Because of the error model, it can also be expressed as: 
( )kij2ij β),θ,h(tσ),t∑
=
==
K
1k
kijijijij ,f(θ;yΦK
1)(yFpd ,                       (5) 
where Φ(x; μ, ω) is the cumulative density function of a univariate normal distribution 
with mean μ and variance ω evaluated at x. If the model f has an analytical expression, 
pdij in Eq. (5) can be easily evaluated by any statistical package in which Φ is 
available. 
 
Standardized Prediction Error 
 Prediction errors for each individual are usually derived using a first order 
linearisation of the model, as in the FO estimation methods (15, 17, 16). Indeed, after 
linearisation, the predictive distribution can be obtained analytically. For instance, the 
linearisation in the case of additive random-effects model yields: 
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  .εb
b
)ξ ,f(
iiT
i +)ξ ,f(ε)ξ ,bf(y iiiii +≈++= μ∂
∂μμ                         (6)  
Because of this approximation, the predictive distribution is normal with mean: 
),ξ ,f()E(y ii μ≈                                                                                      (7) 
 and variance Vi: 
 ).() ,(' μΣ
b
ξ
i
i +∂
μ
'
) ,(
Ω
b
ξV ii ≈ ∂∂
μ∂ ff
      (8) 
Then, for a given observation yij, the prediction error is defined as peij = yij -E(yij), 
where E(yij) is given in Eq. (7). The standardized prediction error is defined, in most 
software, as  
 speij = (yij-E(yij))/SD(yij)                                                 (9) 
where SD(yij) is the square-root of the jth diagonal element of the variance Vi given in 
Eq. (8). In NONMEM, the full predicted variance Vi can be used to evaluate the 
“uncorrelated” vector of standardised prediction errors,  
 spei = Vi-1/2{yi -E(yi)}.        (10) 
This approach provides uncorrelated components speij within an individual i, only if 
the normality of the predictive distribution, which is based on the linearisation, is 
assumed to be valid.  
 Under H0 and based on the first-order approximation, the speij should have a normal 
distribution with mean 0 and variance 1. It is however known that the linearisation 
around the mean is poor if the model is highly nonlinear or if the inter-patient 
variability is large, and then the distribution of speij under  H0 is no longer normal.  
 
 
Tests 
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  We use the theoretical distributions under H0 of prediction discrepancies and 
standardized prediction errors to provide a test of H0 for a given data set of N 
individuals. The idea is to test whether the prediction discrepancies follow a uniform 
U[0,1]  distribution and whether the standardized prediction errors follow a normal 
N(0,1) distribution. Several useful diagnostic plots that were defined for speij can 
easily be applied also for pdij: quantile-quantile plots; histograms; plots of pd versus 
predicted mean concentrations or versus time. 
 A problem arises, when analysing real datasets, for the implementation of  
statistical tests to evaluate whether there is departure from the distributional 
assumption under H0. Indeed, if all observations yij were independent, then all 
prediction discrepancies or errors would be independent and we could use the one-
sample Kolmogorov-Smirnov (KS) test to evaluate the departure from the expected 
distribution under H0. However, in most cases there are several observations within 
one individual, which are only independent given the individual random effects but 
not marginally. In that case the prediction discrepancies and the prediction errors 
(computed as in Eq. (9)) within an individual are not independent. When using 
NONMEM with the prediction errors computed as in Eq. (10) and assuming the first-
order approximation is valid as in a linear mixed-effects model, then they can be 
assumed independent within individuals and this problem no longer holds. These 
correlations within individuals invalidate the previous distributional tests (both on pd 
or spe) because these tests assume a set of independent realisations. The KS test then 
might not be of the expected size, with a wrong type I error.  
 Correlations are often forgotten when validation is performed using speij (15,6). To 
circumvent that problem we propose two approaches. The first one is to apply the test 
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 on only one randomly chosen observation per individual, but obviously this leads to 
loss of power because all observations are not used for model evaluation. The other 
approach is to use a Monte Carlo simulation under H0 to define an empirical threshold 
for the test in order to get the chosen type I error. This is of course a computer-
intensive approach.  
 
 
EVALUATION BY SIMULATION 
Model 
 The basic pharmacostatistical model used for the evaluation by simulation is 
similar to the one in Mentré and Gomeni (12). A one compartment pharmacokinetic 
model with first-order absorption is assumed, corresponding to the following equation: 
   ).e(e
)
V
CL
tktV
CL
a−− −
V(k
Dk
t)f(θ(
a
a
−
=                                                    (11) 
It involves three pharmacokinetic parameters ka, the rate-constant of absorption, Cl, 
the oral clearance of elimination, and V, the oral volume of distribution. The dose D is 
fixed to 10. Exponential random effects are assumed for these three parameters and the 
error model variance is a constant coefficient of variation model, i.e. the variance of 
the error is proportional to the square of the prediction: h(t, θ, β) = f2(θ , t). 
 For the basic model, i.e. under the null hypothesis, the following values are used.  
The fixed effects are 5, 5 and 2 for ka, Cl and V, respectively. A coefficient of 
variation of 30% for interpatient variability is assumed, which corresponds to a 
variance of 0.09 for the distribution of the logarithm of the parameters. The coefficient 
of variation of the error model is 15% which corresponds to σ2 = 0.0225.  
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  Six sampling times are defined: 0.05, 0.15, 0.3, 0.6, 1 and 1.4 after dose 
administration. We simulated two types of data sets both with a total number of 300 
observations. In the first case (Case I), simulated data sets are composed of N = 300 
patients with only n = 1 observation at a sampling time randomly chosen among the 
six defined sampling times. In the second case (Case II), simulated data sets are 
composed of N = 100 patients with n = 3 observations at sampling times chosen 
randomly (without replacement within one individual) among the 6. The first case is 
not very realistic and is interesting only because there is no correlation between the 
observations. The second case is closer to real-life data and is used to evaluate the 
methods when there are correlations. We evaluate two approaches to handle the 
repeated observations within individuals in Case II: in Case IIa, all 300 observations 
are kept and an empirical threshold is computed; in Case IIb only one observation per 
individual is used, randomly chosen among the three available, which leads to a total 
of only 100 observations for model evaluation. 
 
Simulation Setting 
 Data sets are simulated under H0 with the basic model and parameters described 
above, and under several alternative hypotheses with modified parameters and/or 
models. For each alternative hypothesis studied, 1 000 datasets for Case I and 1 000 
sets for Case II are simulated. Each set is simulated as follows. First, random effects 
are sampled from a normal distribution and individual parameters are derived. Second, 
sampling times are randomly chosen and predicted concentrations are calculated from 
the model. Third, concentrations are simulated by multiplying the predicted 
concentration by 1 + ε, where ε is a random sample of a zero-mean normal distribution 
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 with variance σ2. Fig. 1 displays a typical set of pseudo-observed concentrations for 
the basic model with the prediction for the mean parameters overlaid.  
 In a first stage, simulations are performed under H0 to evaluate the type I error and 
to determine the empirical thresholds to be used in the evaluation of the power. The 
empirical threshold, for a given simulation, is defined as the 95% percentile of the KS 
distances under H0, i.e. the 950th value once the 1 000 KS distances are ordered. 
 In a second stage, data sets are generated under alternative assumptions 
corresponding to the same models but with successive changes in the value of the 
parameters. First, each fixed effect is separately multiplied or divided by two (6 
cases). Second, the coefficient of variation of each random effect is separately 
multiplied or divided by two and then all together (8 cases). Third, the error 
coefficient of variation is multiplied or divided by two (2 cases). Thus we define a 
total of 16 alternative hypotheses based only on numerical modifications of the 
population parameters. The first group of simulations with changes on the fixed effects 
are mostly performed to check the approaches and their implementation. Indeed, such 
important changes in fixed effects can usually be seen visually and do not need such 
complex tests for which we expect a good power. We are indeed more interested in the 
other groups of simulations under H1, where change are made on the variances or on 
the model (see below), because these changes are more difficult to check visually.   
 In a third stage, we assume an alternative pharmacokinetic model. We simulate data 
under a two-compartment model with first order absorption. The parameters of this 
model are chosen in order to be close to the one compartment model. We also chose 
typical values for Cl, V, and ka and variabilities for these parameters similar to those 
from the basic model. The two inter-compartmental rate constants, k12 and k21, are 
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 fixed respectively to 2.1 and 2.4, without inter-patient variability. The two mean rate 
constants λ1 and λ2 are then respectively 6 and 1, compared to the mean elimination 
rate constant of 2.5 (k = Cl/V) in the one-compartment model.  
 In the fourth and last stage, we assume that the distribution of the random effects 
for Cl is a mixture of two normal distributions. More precisely, the distribution for 
log(Cl) under the null hypothesis is N(1.6; 0.09). The alternative distribution is a 
mixture of the same distribution N(1.6; 0.09) with a weight of  0.75  and of  N(2.2; 
0.0225) with a weight of 0.25. This intends to mimic a validation set where one fourth 
of the patients would come from a different population. 
 
Evaluation method 
 The simulated sets are considered as validation sets and the null assumption is the 
basic model with the basic population parameters μ, Ω, σ. In a real-life analysis, these 
“basic” parameters could have been for instance those estimated on a separate data set 
(in the case of external validation) or on the same data set (in the case of internal 
validation). As already mentioned we do not take into account the estimation error in 
our predictive distribution, so that we do not need to perform estimation on the 
simulated datasets to evaluate the statistical properties of the prediction criteria.  
 The method proposed to evaluate prediction discrepancies given in Eq. (5), with 
K =10 000 Monte Carlo samples, is applied to each observation of a simulated set 
using the basic values for the population parameters. Similarly, the standardized 
prediction error for each observation of a simulated set is evaluated as in Eq. (9) using 
the analytical expression of the derivatives of the model. In order to get similar 
distributional assumptions for testing pd and spe, the latter are transformed using the 
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 normal cumulative density function Φ. More precisely, Φ(spe) are evaluated and, 
under the assumption that spe follow a N(0,1) distribution, Φ(spe) follow a U(0, 1) 
distribution.  
 A KS test for a U(0,1) distribution is then applied on the samples of pd or spe 
evaluated from the pseudo-observations of each simulated set. The distance limit of 
this test for 300 observations (Cases I and IIa) and a type I error of 0.05 is 0.078.  For 
100 observations (Case IIb) the distance limit is 0.136.  
 
Numerical Implementation 
 All computations were done on a Sun Ultra1 Workstation. The procedures used in 
this paper were implemented in the Pascal programming language. The pseudorandom 
generator is that of Sun Pascal Compiler 4.2 release, for Solaris 5.1.1. The algorithm 
for generating normally distributed numbers is the routine named « gasdev » in 
Numerical Recipes. Descriptive statistical analyses were performed in SAS 8.1. 
 
Results 
Type I error 
 The type I errors evaluated on the 1000 replications for cases I (N=300, n=1), IIa 
(N=100, n=3) and IIb (N=100, n=1) are reported in Table I for both evaluation criteria 
(spe and pd). For spe, they are 25.3 % , 34.7 % and 11 % for cases I, IIa and IIb 
respectively, values that are much greater than the nominal 5% level. The increase of 
type I errors for spe in the two cases (I and IIb) when there is no correlation between 
observations is wholly attributable to the first-order approximation of the model. The 
highest type I error is observed for case IIa can also be explained by the correlation 
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 within individuals. With the method implemented in NONMEM (as in Eq. (10)) to 
evaluate uncorrelated WRES, the type I error would have been closer to those of the 
two other case. This method is, however, not evaluated here because, first it is only 
implemented in NONMEM and not in other statistical packages, and, second the main 
limitation of using spe is already apparent with independent observations (cases I and 
IIb)  
 Interestingly, for the prediction discrepancies in cases I and IIb (i.e., in the absence 
of correlation in the observations) the empirical type I errors are close to 5 %: 3.8 % 
and 5.8 %, respectively. We anticipated this good behavior because no approximation 
is made in pd evaluation. There is however an increase in the type I error to 10.9% in 
the case of correlated observations within individuals (case IIa), but the type I error 
still remains much lower than for spe. Fig. 2 displays several goodness-of-fit plots for 
spe and pd for one simulated set under the null hypothesis in case IIb.  
 
Power  
 The empirical thresholds of the KS tests estimated from the 1 000 simulations 
under H0 are used for the evaluation of the power of the tests under several 
alternatives. They are .098, .111, .153 for spe in cases I, IIa and IIb respectively and 
.076, .088, .139 for pd.  
 The powers of the tests for the several alternatives are given in Table I. It can be 
seen that the power to detect a systematic deviation on the fixed-effect parameters 
(multiplied or divided by two) is, as expected, very high (greater than 99 %) for V and 
Cl regardless of the case and method used. The power is slightly lower for ka probably 
because of the experimental design where only few samples during the absorption 
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 phase are available.   
 For all the alternative assumptions based on changes in the variability of the 
parameters or of the error, it can be seen that the power using spe is consistently lower 
than when using pd, and the loss is sometimes important, especially in case IIa. For 
instance, for increased variability on Cl or V in case IIa, the power is respectively 36.6 
and 52.4 % for spe versus 75.8 % and 87.3 % for pd. This is partly due to the fact that 
the empirical threshold used in order to maintain a type I error of 5% is greater for spe 
than for pd. In general, the powers of tests based on pd to detect increased variability 
on Cl and V are satisfactory, except for case IIb where the loss of power compared to 
case I, and even to case IIa with a corrected threshold, is obvious and is due to the 
decrease of the number of samples. We note that the power to detect a decrease of 
variability for Cl or V is lower than for an increase of variability. This may be a 
consequence of the low variability assumed here, 30%, which is then reduced to 15%. 
However, when the variability changes for all three parameters (multiplied or divided 
by two), the power is again close to 100% for both methods. Fig. 3 displays the same 
goodness-of-fit plots than Fig. 2, but one simulated set of case IIa where variability on 
Cl is multiplied by two. These plots illustrate the use of pd also graphically without 
formal testing. 
 The power to detect changes in the variability on ka is smaller than for V and Cl, 
and again this could be explained by the experimental design. The power to detect 
changes in the variance of the residual error is lower than for the changes on the 
variability of the random effects, and again is much smaller when it is divided by two 
than when it is multiplied by two. It is also lower for spe compared to pd.  
 The last two lines of Table I report the power for changes not in the parameters 
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 values but in the population model itself. First, a two-compartment model is simulated 
instead of a one-compartment model. The power for cases I and IIa is high, greater 
than 90%, although the alternative hypothesis is chosen to be not too far from the null. 
It is interesting to notice that this is the only case where spe have similar (or even 
greater) power than pd. Fig. 4 displays the goodness-of-fit plots for spe and pd for one 
simulated set in case IIa with a two-compartment model. It can be seen in the graph of 
box-plot of errors versus time, a clear trend towards smaller errors for times just after 
the peak (0.3, 0.6) and larger errors for later times (1.4). The last alternative 
assumption is when Cl is distributed as a mixture on the validation set and the power 
is again very high, except for case IIb where the total number of observations is only 
one third that of cases I and IIa. 
 
 
DISCUSSION 
 We develop a criterion and a test for nonlinear mixed-effects model evaluation 
based on prediction discrepancies. The evaluation of these discrepancies by Monte 
Carlo integration, that is to say based on simulated samples from the distribution of the 
random effects, is not difficult, especially if the structural model f has an analytical 
solution. For more complex models, the pd in Eq. (3) can also be evaluated using the 
simulated capacities of the estimation software as for instance in NONMEM. In that 
case, K sets of observations with the same design features as the validation set are 
simulated under the null population model. Then, for each observation, its percentile 
on the sample of simulated observations is evaluated, and it is an estimate of the 
associated pd.  This method was used by Comets et al (27) in a recent application of 
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 the use of prediction discrepancies for comparison of real pharmacokinetic data 
obtained in two different populations of patients.  
 We do not incorporate covariates in the method section and in the simulations, but 
it is straightforward to extend the method to models with additional fixed effects 
quantifying the relationship between parameters and individual covariates zi. In the 
evaluation of the predictive distribution, the observed value zi of each individual is 
then used. 
 To test a null model H0 using pd, we propose to use a KS test to check for 
departures from a U[0, 1] distribution. We evaluate that test and compare its 
performance to a test based on spe in a simulation study. In the simulation study, we 
mimic the case where the validation data set is a separate data set and not the one used 
for model development and for parameter estimation. Therefore no estimation is 
performed during the simulation because the null model H0 was given, and only 
validation sets are simulated. We also illustrate that prediction discrepancies can be 
used in graphs to visually assess the distance between model and data (similarly to 
graphsfor residuals or for errors) without testing formally model’s correctness as 
suggested by Gelman (28). These diagnostic plots can help to detect where the model 
may fail. 
 The simulations under H0 have shown, for validation sets with independent 
observations, a type I error close to the nominal level for the test based on pd. Using 
spe the type I error is greatly increased (25.3 % in Case I), which can be only 
explained by the poor statistical property of this criterion which uses a linearisation of 
the model.  We do find an increased type I error, for both pd and spe, in the more usual 
case where there are repeated measurements within individuals (Case II.a), but less for 
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 pd (10.9 %) than for spe (34.7 %). The increased type I error is the result of the 
correlation between the errors within one individual, which invalidates the assumption 
of the KS test, and appears for both criteria since it is not related to model linearisation 
but to the distributional test itself. In this paper, we propose to solve that problem of 
repeated observations by using an empirical threshold estimated using a Monte Carlo 
simulation under H0, a procedure that can be rather cumbersome. 
 The simulations show the satisfactory power of the proposed approach, for a 
validation sample of a total of 300 observations, to detect departure from H0 either in 
the parameter values or in the model assumptions. It is interesting to note that the 
power is satisfactory in the case when there is only one observation per individual but 
in 300 patients (Case I). The power is much lower when only one third of the 
observations are used (case IIb). The power for spe is lower than for pd, and this could 
be simply a consequence of using a higher threshold for spe because of the increased 
type I error under H0. Consequently, even though pd may be more complex to evaluate 
than spe, the use of the latter not only implies to always estimate an empirical 
threshold, but also leads to a lower power.  
 The main limitation of the proposed approach based on pd is that it does not take 
into account the correlation within individuals with repeated observations, which are 
the most usual cases in population PK. We did not perform simulations for a richer 
design with for instance 10 samples per individual, because the problem is already 
apparent with 3 observations per individual and it would have been even bigger. We 
did not computed uncorrelated spe as proposed in NONMEM, because spe showed 
rather poor properties even for only one observation per patient. It is fair to note that 
for Case II.a, doing a test based on uncorrelated spe as in NONMEM would have lead 
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 to a better Type I error than the one with standard spe as evaluated here. The tests 
could have performed better, in that case, than using pd. We propose here to use 
empirical thresholds, but we think that other statistical developments are needed. One 
idea would be to use a rather similar approach than in NONMEM, in order to obtain 
uncorrelated pseudo-observations in each patient. Using K simulated data sets under 
the null model, the expected variance matrix for each vector of observation of an 
individual could be empirically estimated without linearisation. Then using a Cholesky 
decomposition as in Eq. (10), uncorrelated vector of pseudo-observations could be 
derived. These vectors would have independent observations within one individual. 
Then, for each pseudo-observation a pd could be computed using the predictive 
distribution of the pseudo-observation instead of the predictive distribution of the real 
observation. This method should be implemented and evaluated. It could then be 
compared to spe as computed in NONMEM where the evaluation of the mean and 
variance are based on a linearization of the model.  
 We can also suggest a model evaluation “strategy” based on pd in order to try to 
avoid the computer intensive estimation of the empirical threshold in the present form 
of the test. In a first step, the KS test is performed with only one sample per individual 
randomly chosen in the validation set. If there is a significant departure from H0, the 
model is rejected and no correction of the threshold is needed because there is no 
correlation between pd. If it is not rejected, then, in a second step, the approach should 
be applied to all observations, to avoid a lack of power of the previous test, using then 
a Monte Carlo p-value approach. 
 It should be noted that the null hypothesis in all the proposed approaches is that the 
model is correct, so that we can only invalidate a model when we reject H0. When H0 
 23  
H
AL author m
anuscript    inserm
-00156908, version 1
 is not rejected, it can always be due to a lack of power because for instance of a poor 
design in the set used for ‘evaluation’. It is for instance illustrated here with a small 
power to detect changes in ka. There is a strong link between design and model 
evaluation: for instance a linear model is only valid for a given range of doses. 
Therefore, as H0  is never accepted, ‘Absence of evidence is not evidence of absence’, 
a model will never be significantly correct with these methods. Approaches based on 
the idea of equivalence testing could perhaps be developed, in which the alternative 
hypothesis would be that the observations are close enough to the model.  
 There are several similarities between the proposed criterion, i.e. prediction 
discrepancy, and the approach proposed by Yano, Beal and Sheiner (6). They also 
used random samples of the parameters to do Monte Carlo integration for evaluation 
of posterior predictive checks (PPC). The cumulative distribution of the predictive 
distribution for one observed statistic was also evaluated. Here we restrict ourselves to 
the observations themselves, which would correspond to a two-sided PPC. Like us, 
Yano Beal and Sheiner used a KS test (6). Other tests of distributional assumptions 
could be used like the Anderson and Darling test or the Cramer van Mises test, which 
would perhaps have greater power (29). There are also similarities with the approach 
proposed by Lange and Ryan (22) who tested the distributional assumption of the 
random effects in linear mixed-effects models by comparing the expected and 
empirical cumulative distribution functions of the random effects. They used weighted 
empirical cumulative distribution functions of linear combinations of random effects 
and they adjusted the covariance to take into account both the correlation within 
individuals and the estimation of the unknown parameters. This idea could perhaps be 
extended to empirical cumulative distribution functions on observations, as done here, 
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 in order to try to take account correlations within individuals. Again, the nonlinearity 
of the model makes it not straightforward to apply.  
 The present work concerns the evaluation of a composite null model where the 
parameters are unknown and have been estimated by MLE. As recalled in the 
introduction, we do not evaluate an exact predictive distribution. As in the plug-in 
approaches (20,21), the posterior distribution of the parameters is assumed to be 
located only at the MLE which is the simplest approach in this framework. This 
limitation is the same for errors based on pd or on spe but is perhaps not major. 
Indeed, in their evaluation by simulation of PPC in individual nonlinear regression, 
Yano, Beal and Sheiner (6) showed that this approach to evaluate the posterior 
distribution in the maximum likelihood framework was “as good as either of the 
others” and that the test was conservative. Also, Bayarri and Berger (20) pointed out 
the fact that the criterion mostly used by Bayesian statisticians, which is based on the 
full posterior predictive distribution, makes somehow a “double use” of the data. They 
concluded their paper by suggesting that, in practice, p-values based on this plug-in 
approach seem preferable over those based on the posterior predictive distribution, 
even though they may be conservative. This explains why both they and Robins, van 
der Vaart and Ventura (21) proposed, compared and evaluated new criteria based on 
partial predictive, conditional predictive or conditional plug-in distributions, which we 
do not study here.  
 The problem of how model evaluation should be performed when there is not 
clearly an external dataset is not clear. Prediction discrepancies can be evaluated either 
on observations used for model building and estimation or on separate observations. 
We believe that it is preferable to randomly split the data to perform model evaluation 
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 on data not used for model building. This is the approach we mimic in our simulation 
study. Evans (19) recommends that approach and proposes that the validation set be 
randomly chosen as 25% of the total data set. In the FDA guidance, random splitting is 
also suggested (16).  
  All these discussion points confirm that model evaluation is a difficult task 
which depends of the objective of the analysis. The best way to conclude may be to 
quote McCullag and Nelder who wrote in the introduction of their book on 
Generalized Linear Models in 1989 (30): “Modelling in science remains, partly at 
least, an art. A first principle is that all models are wrong; some, though, are more 
useful than others and we should seek those. A second principle (which applies also to 
artists!) is not to fall in love with one model to the exclusion of alternatives. A third 
principle recommends thorough checks on the fit of a model to the data. Such 
diagnostic procedures are not yet fully formalised, and perhaps never will be. Some 
imagination or introspection is required in order to determine the aspects of the model 
that are most important and most suspect.”  We think that that prediction discrepancies 
as developed here could be helpful in these diagnostics steps and are a good 
alternative to usual standardized prediction errors.   
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  Table I. Type I error and power under several alternative assumptions (in %) of the 
KS test for standard prediction errors (spe) and for prediction discrepancies (pd) 
evaluated on 1000 simulated data sets under the 3 studied cases with various 
number of individuals (N) and number of samples per individual (n). 
 
Assumptions Case I (N=300, n=1) Case II (N=100) 
   Case IIa (n=3) Case IIb (n=1) 
       spe pd   spe pd spe pd 
H0 25.3 3.8 34.7 10.9 11.0 5.8 
       
V × 2 100 100 100 100 100 100 
Cl × 2 100 100 100 100 100 100 
ka × 2 98.7 99.7 93.6 98.8 54.4 69.3 
V / 2 100 100 100 100 96.2 99.0 
Cl / 2 100 100 100 100 100 100 
ka  / 2 100 100 100 100 94.4 96.5 
       
CVv × 2 54.7 91.3 36.6 75.8 20.4 33.8 
CVCl × 2 73.2 97.3 52.4 87.3 23.0 40.1 
CV ka × 2 18.6 42.1 10.5 28.6 10.2 11.9 
All CV × 2 100 100 99.8 100 85.1 96.6 
CVv / 2 14.2 21.5 7.6 15.4 4.3 5.1 
CVCl / 2 37.7 53.6 15.6 32.5 10.7 11.5 
CVka / 2 8.8 9.0 6.1 6.8 4.8 3.6 
All CV / 2 100 100 100 100 78.6 85.0 
CVε × 2 25.1 59.2 15.5 38.8 10.5 16.8 
CVε / 2 7.7 8.2 4.7 8.7 3.3 4.8 
       
2cp model 99.8 99.7 96.9 93.1 77.1 71.3 
Cl mixture 96.8 98.0 85.9 98.1 58.8 30.9 
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 Figure captions 
 
Fig. 1. Typical data set containing 300 simulated pseudo-observed concentrations and 
mean-predicted concentrations for the basic model, in case IIa (N=100, n=3). 
 
Fig. 2. Goodness-of-fit plots under H0, for standardized prediction errors (top) or for 
prediction discrepancies (bottom), for one simulation in case IIa (N=100, n=3). Left: 
quantile-quantile plot for a uniform distribution; middle: histograms of errors; right: box 
plots of the 50 errors at each sampling time versus time.  
 
Fig. 3. Goodness-of-fit plots under the alternative assumption that the variability of Cl is 
multiplied by two, for standardized prediction errors (top) or prediction discrepancies 
(bottom), for one simulation in case IIa (N=100, n=3) (see legend of Fig. 2 for more 
details). 
 
Fig. 4. Goodness-of-fit plots under the alternative assumption that the pharmacokinetic 
model is a two-compartment model, for standardized prediction errors (top) or prediction 
discrepancies (bottom), for one simulation in case IIa (N=100, n=3) (see legend of Fig. 2 
for more details).   
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 Figure 1 
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 Figure 2 
 35  
H
AL author m
anuscript    inserm
-00156908, version 1
 Figure 3 
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 Figure 4 
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